The European Commission (EC) has approved anti-VEGF therapy Beovu (brolucizumab) 6 mg for diabetic macular edema (DME), marking the therapy’s second indication in the bloc.
Read More
Beovu AMD therapy now listed on the PBS
Almost 13,000 Australians could save thousands annually with the Pharmaceutical Benefits Scheme (PBS) listing of Beovu (brolucizumab) for neovascular age-related macular degeneration (nAMD) from this month, the Federal Government says.
Read More
Read More
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment.
Read More
Read More
Anti-VEGF becomes most expensive drug on PBS
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a hepatitis C drug to become the costliest subsidised drug for the first time.
Read More
Read More
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME).
Read More
Read More
Novartis provides safety update for Beovu
A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases.
Read More
Read More
Novartis AMD drug Beovu secures European approval
European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new anti-VEGF therapy.
Read More
Read More
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country.
Read More
Read More
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors.
Read More
Read More
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea.
Read More
Read More